The effects of MD-Fraction, a β-glucan extracted from Maitake mushroom (Grifola frondosa), on the health status of individuals suffering from HIV infection were evaluated in a long-term trial. The HIV status of the 35 respondents who participated in the study was followed by monitoring CD4+ cell counts, viral load measure, symptoms of HIV infection, status of secondary disease, and sense of well-being. Twenty patients reported an increase in CD4+ cell counts to 1.4–1.8 times, and 8 patients reported a decrease to 0.8–0.5 times. Viral load was reported to increase in 9 patients and decrease in 10 patients. However, 85% of respondents reported an increased sense of well-being with regard to various symptoms and secondary diseases caused by HIV. These results suggest that Maitake D-Fraction had a positive impact in HIV patients.
This is a preview of subscription content, log in to check access.
Hishida I., Nanba H. and Kuroda H. 1988. Anti-tumor activity exhibited by oral administered extract from fruit body ofGrifola frondosa (Maitake). Chem. Pharm. Bull.36: 1819–1827.
Nanba H., Hamaguchi A. and Kuroda H. 1987. The chemical structure of an anti-tumor polysaccharide in fruit bodies ofGrifola frondosa (Maitake). Chem. Pharm. Bull.35: 1162–1168.
Nanba H. and George S. R. 1993. Effects of Maitake (Grifola frondosa) for HIV-positive or fibroid tumor patients. 113th Congr. Pharmaceutical Society of Japan, Osaka, Japan, March 29–31, p. 212.
Nanba H. 1993. Anti-tumor activity of orally administered D-Fraction from Maitake mushroomGrifola frondosa. J. Naturopath. Med.4: 10–15.
About this article
Cite this article
Nanba, H., Kodama, N., Schar, D. et al. Effects of Maitake (Grifola frondosa) glucan in HIV-infected patients. Mycoscience 41, 293–295 (2000). https://doi.org/10.1007/BF02463941
- anti-HIV activity
- CD4+ cell
- Grifola frondosa (Maitake)